ASTROCYTOMA, IDH-MUTANT, GRADE 2
Clinical trials for ASTROCYTOMA, IDH-MUTANT, GRADE 2 explained in plain language.
Never miss a new study
Get alerted when new ASTROCYTOMA, IDH-MUTANT, GRADE 2 trials appear
Sign up with your email to follow new studies for ASTROCYTOMA, IDH-MUTANT, GRADE 2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for brain cancer patients
Disease control OngoingThis early-phase trial tests a new drug (telaglenastat) combined with standard radiation and chemotherapy for people with a specific type of brain tumor (IDH-mutated astrocytoma). The main goal is to find the safest dose and see if the combination shrinks tumors. About 40 adults …
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 2
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:01 UTC
-
Experimental drug combo targets recurrent brain cancer
Disease control TerminatedThis early-stage trial tests the safety and best dose of the drug triapine combined with radiation therapy for people whose glioblastoma or astrocytoma has returned. Triapine may slow tumor growth by blocking certain enzymes, while radiation aims to kill cancer cells. The study i…
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 2
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC